Hemostemix Closes Private Placement of USD $336,500 at $0.295 per Share
Hemostemix (OTCQB: HMTXF) has completed a non-brokered private placement of USD $336,500, issuing 1,634,466 common shares at CAD $0.295 per share to CytoImmune Therapeutics LLC. The proceeds will be used for general working capital and business development activities.
The company is an autologous stem cell therapy platform developer that has completed seven clinical studies involving 318 subjects. Their lead product, ACP-01, has shown significant results in treating various conditions including peripheral arterial disease and chronic limb threatening ischemia (CLTI). Notable results from their Phase II CLTI trial showed 0% mortality and wound healing in 83% of patients, compared to the typical 60% five-year mortality rate.
Hemostemix (OTCQB: HMTXF) ha completato un collocamento privato senza intermediari per un importo di 336.500 USD, emettendo 1.634.466 azioni ordinarie a CAD 0,295 per azione a favore di CytoImmune Therapeutics LLC. I proventi saranno utilizzati per il capitale circolante generale e le attività di sviluppo aziendale.
L'azienda è uno sviluppatore di piattaforme per terapie con cellule staminali autologhe e ha completato sette studi clinici coinvolgendo 318 soggetti. Il loro prodotto principale, ACP-01, ha mostrato risultati significativi nel trattamento di diverse condizioni, tra cui la malattia arteriosa periferica e l'ischemia cronica minacciosa degli arti (CLTI). I risultati notevoli della loro fase II sul CLTI hanno evidenziato un tasso di mortalità dello 0% e una guarigione delle ferite nell'83% dei pazienti, rispetto al tipico tasso di mortalità del 60% a cinque anni.
Hemostemix (OTCQB: HMTXF) ha completado una colocación privada sin intermediarios por un total de 336,500 USD, emitiendo 1,634,466 acciones ordinarias a CAD 0.295 por acción a CytoImmune Therapeutics LLC. Los fondos se destinarán al capital de trabajo general y a actividades de desarrollo empresarial.
La compañía es desarrolladora de una plataforma de terapia con células madre autólogas y ha completado siete estudios clínicos con 318 sujetos. Su producto principal, ACP-01, ha mostrado resultados significativos en el tratamiento de diversas condiciones, incluyendo la enfermedad arterial periférica y la isquemia crónica amenazante de extremidades (CLTI). Resultados destacados de su ensayo de fase II en CLTI mostraron una mortalidad del 0% y cicatrización de heridas en el 83% de los pacientes, comparado con la tasa típica de mortalidad del 60% a cinco años.
Hemostemix (OTCQB: HMTXF)는 중개인 없이 336,500달러 규모의 사모 발행을 완료했으며, CytoImmune Therapeutics LLC에 주당 CAD 0.295에 1,634,466 보통주를 발행했습니다. 자금은 일반 운전자본 및 사업 개발 활동에 사용될 예정입니다.
이 회사는 자가 줄기세포 치료 플랫폼 개발업체로서 318명의 대상자를 포함한 7건의 임상시험을 완료했습니다. 주력 제품인 ACP-01은 말초 동맥 질환과 만성 사지 허혈(CLTi) 등 다양한 질환 치료에서 유의미한 결과를 보였습니다. 2상 CLTI 임상시험 결과, 사망률 0%와 83%의 상처 치유율을 기록했으며, 이는 일반적인 5년 사망률 60%와 비교해 매우 우수한 수치입니다.
Hemostemix (OTCQB : HMTXF) a finalisé un placement privé sans intermédiaire d'un montant de 336 500 USD, émettant 1 634 466 actions ordinaires au prix de 0,295 CAD par action à CytoImmune Therapeutics LLC. Les fonds seront utilisés pour le fonds de roulement général et les activités de développement commercial.
L'entreprise est développeur d'une plateforme de thérapie par cellules souches autologues et a mené à bien sept études cliniques impliquant 318 sujets. Leur produit principal, ACP-01, a montré des résultats significatifs dans le traitement de diverses pathologies, notamment la maladie artérielle périphérique et l'ischémie chronique menaçante des membres (CLTI). Les résultats remarquables de leur essai de phase II sur le CLTI ont révélé un taux de mortalité de 0 % et une cicatrisation des plaies chez 83 % des patients, contre un taux de mortalité typique de 60 % sur cinq ans.
Hemostemix (OTCQB: HMTXF) hat eine privat platzierte Kapitalerhöhung ohne Vermittler in Höhe von 336.500 USD abgeschlossen und 1.634.466 Stammaktien zu einem Preis von CAD 0,295 pro Aktie an CytoImmune Therapeutics LLC ausgegeben. Die Erlöse werden für das allgemeine Betriebskapital und Geschäftsentwicklungsaktivitäten verwendet.
Das Unternehmen ist Entwickler einer autologen Stammzelltherapie-Plattform und hat sieben klinische Studien mit insgesamt 318 Probanden abgeschlossen. Ihr Hauptprodukt ACP-01 zeigte signifikante Ergebnisse bei der Behandlung verschiedener Erkrankungen, darunter periphere arterielle Verschlusskrankheit und chronisch kritische Extremitätenischämie (CLTI). Bemerkenswerte Ergebnisse der Phase-II-Studie bei CLTI zeigten eine Sterblichkeitsrate von 0 % und eine Wundheilung bei 83 % der Patienten, verglichen mit der üblichen Fünfjahressterblichkeitsrate von 60 %.
- None.
- Reliance on external financing for working capital needs
- Potential dilution to existing shareholders from share issuance
Calgary, Alberta--(Newsfile Corp. - May 12, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company"), per the Company's February 4, 2025 news release, closed the previously announced USD
Per Policy 4.1., Cytoimmune Therapeutics LLC is arm's length to the Company and is not a Related Party to the Company at the time of disclosure.
The use of proceeds will be allocated to general working capital purposes, including business development activities.
The Company confirms that there is no material fact or material change about the Company that has not been generally disclosed.
ABOUT HEMOSTEMIX
Hemostemix is an autologous stem cell therapy platform company, founded in 2003. A winner of the World Economic Forum Technology Pioneer Award, the Company has developed, patented, is scaling and selling autologous (patient's own) blood-based stem cell therapies that include angiogenic cell precursors (ACP-01). Hemostemix has completed seven clinical studies of 318 subjects and published its results in nine peer reviewed publications. ACP-01 is safe, clinically relevant and statistically significant as a treatment for peripheral arterial disease, chronic limb threatening ischemia, non ischemic dilated cardiomyopathy, ischemic cardiomyopathy, congestive heart failure, and angina. Hemostemix completed its Phase II clinical trial for chronic limb threatening ischemia and published its results in the Journal of Biomedical Research & Environmental Science. As compared to a five year mortality rate of
For further information, please contact: Thomas Smeenk, President, CEO & Co-Founder
EM: tsmeenk@hemostemix.com PH: 905-580-4170
Neither the TSX Venture Exchange nor its Regulation Service Provider (as that term is defined under the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Forward-Looking Information: This news release contains "forward-looking information" within the meaning of applicable Canadian securities legislation. All statements, other than statements of historical fact, included herein are forward-looking information. In particular, this news release contains forward-looking information in relation to sales of its lead product ACP-01, the commercialization of ACP-01 via the sale of compassionate treatments under Special Access Programs. There can be no assurance that such forward-looking information will prove to be accurate. Actual results and future events could differ materially from those anticipated in such forward-looking information. This forward-looking information reflects Hemostemix's current beliefs and is based on information currently available to Hemostemix and on assumptions Hemostemix believes are reasonable. These assumptions include, but are not limited to: the underlying value of Hemostemix and its Common Shares; the successful resolution of any litigation that Hemostemix is pursuing or defending (the "Litigation"); the results of ACP-01 research, trials, studies and analyses, including the analysis being equivalent to or better than previous research, trials or studies; the receipt of all required regulatory approvals for research, trials or studies; the level of activity, market acceptance and market trends in the healthcare sector; the economy generally; consumer interest in Hemostemix's services and products; competition and Hemostemix's competitive advantages; and, Hemostemix obtaining satisfactory financing to fund Hemostemix's operations including any research, trials or studies, and any Litigation. Forward-looking information is Subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of Hemostemix to be materially different from those expressed or implied by such forward-looking information. Such risks and other factors may include, but are not limited to: the ability of Hemostemix to complete clinical trials, complete a satisfactory analyses and file the results of such analyses to gain regulatory approval of a phase II or phase III clinical trial of ACP-01; potential litigation Hemostemix may face; general business, economic, competitive, political and social uncertainties; general capital market conditions and market prices for securities; delay or failure to receive board or regulatory approvals; the actual results of future operations including the actual results of future research, trials or studies; competition; changes in legislation affecting Hemostemix; the timing and availability of external financing on acceptable terms; long-term capital requirements and future developments in Hemostemix's markets and the markets in which it expects to compete; lack of qualified, skilled labour or loss of key individuals; and risks related to the COVID-19 pandemic including various recommendations, orders and measures of governmental authorities to try to limit the pandemic, including travel restrictions, border closures, non-essential business closures service disruptions, quarantines, self-isolations, shelters-in-place and social distancing, disruptions to markets, disruptions to economic activity and financings, disruptions to supply chains and sales channels, and a deterioration of general economic conditions including a possible national or global recession or depression; the potential impact that the COVID-19 pandemic may have on Hemostemix which may include a decreased demand for the services that Hemostemix offers; and a deterioration of financial markets that could limit Hemostemix's ability to obtain external financing. A description of additional risk factors that may cause actual results to differ materially from forward-looking information can be found in Hemostemix's disclosure documents on the SEDAR+ website at www.sedarplus.ca. Although Hemostemix has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. Readers are cautioned that the foregoing list of factors is not exhaustive. Readers are further cautioned not to place undue reliance on forward-looking information as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Forward-looking information contained in this news release is expressly qualified by this cautionary statement. The forward-looking information contained in this news release represents the expectations of Hemostemix as of the date of this news release and, accordingly, it is Subject to change after such date. However, Hemostemix expressly disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as expressly required by applicable securities law.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/251675
FAQ
What is the size and price of HMTXF's latest private placement?
What are the clinical trial results for Hemostemix's ACP-01 treatment?
How many clinical studies has Hemostemix (HMTXF) completed?
What will Hemostemix use the private placement proceeds for?
What conditions does Hemostemix's ACP-01 therapy treat?
